The 10th edition of the Melanoma Bridge certainly could not miss Omid Hamid. This year, the director of Immunotherapy and Translational Research at The Angeles Clinic and Research Institute in Los Angeles told us about the opportunity to rethink trial design in order to benefit melanoma patients.
FONTE: www.oncoinfo.it
